Gecacitinib Plus Luspatercept in Patients With Myelofibrosis and Anemia
Gecacitinib Combined With Luspatercept in Patients With Myelofibrosis and Anemia: A Single-center, Prospective, Single-arm Study
This single-center, prospective, single-arm study aims to evaluate the efficacy and safety of gecacitinib combined with luspatercept in patients with myelofibrosis and anemia who have not previously received a Janus kinase inhibitor. Participants will receive oral gecacitinib and subcutaneous luspatercept.
研究概览
地位
地位
干预/治疗
干预/治疗
研究类型
研究类型
注册 (估计的)
注册
阶段
阶段
- 阶段2
联系人和位置
学习联系方式
学习联系方式
- 姓名:Bing Han
- 电话号码:01065295027
- 邮箱:hanbing_li@sina.com.cn
参与标准
资格标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Age 18 years or older.
- Confirmed primary myelofibrosis according to the 2016 World Health Organization diagnostic criteria, or post-polycythemia vera or post-essential thrombocythemia myelofibrosis according to the International Working Group for Myeloproliferative Neoplasms Research and Treatment diagnostic criteria.
- Intermediate-2 or high-risk disease according to the Dynamic International Prognostic Scoring System (DIPSS) or DIPSS-plus, or intermediate-1-risk disease with hepatosplenomegaly that is unresponsive to existing treatment and requires treatment.
- No previous treatment with a Janus kinase inhibitor.
- Discontinuation of other myelofibrosis treatments, such as interferon or hydroxyurea, immunosuppressants, corticosteroids, and growth factors such as erythropoietin, for at least 2 weeks or 6 half-lives before study treatment.
- Splenomegaly, with the spleen palpable 5 cm below the left costal margin.
- Hemoglobin below 100 g/L, with or without red blood cell transfusion dependence.
- Platelet count of at least 75 × 10^9/L.
- Absolute neutrophil count of at least 1.0 × 10^9/L.
- Peripheral blood blasts of 10% or less.
- Eastern Cooperative Oncology Group performance status of 0-2 and a life expectancy of more than 6 months.
- Ability to independently provide written informed consent.
Exclusion Criteria:
-
Clinically significant anemia associated with iron, vitamin B12, or folate deficiency; autoimmune or hereditary hemolytic anemia; gastrointestinal bleeding; or thalassemia.
-
Active infection.
-
A history of malignancy within the previous 5 years, except for cured basal cell carcinoma of the skin or cervical carcinoma in situ.
-
Significant hepatic or renal dysfunction, or dysfunction of another major organ.
-
Other serious conditions that, in the investigator's judgment, may affect participant safety or compliance, including:
- Uncontrolled diabetes mellitus, with blood glucose above 250 mg/dL or 13.9 mmol/L.
- Hypertension that cannot be controlled to a systolic blood pressure below 160 mmHg and a diastolic blood pressure below 100 mmHg despite combination antihypertensive treatment.
- Peripheral neuropathy of grade 2 or higher according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0.
-
Previous splenectomy.
-
Previous treatment with any transforming growth factor-beta ligand inhibitor.
-
Pregnancy or breastfeeding, women planning pregnancy during the study, or men with near-term plans to father a child.
-
Suspected hypersensitivity to gecacitinib, luspatercept, or drugs of the same class.
-
Any other condition that, in the investigator's judgment, makes the participant unsuitable for the study.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
手臂数量
武器和干预
参与者组/臂参与者组/臂 |
干预/治疗干预/治疗 |
|---|---|
|
实验性的:Gecacitinib + Luspatercept
gecacitinib 100 mg orally twice daily, combined with luspatercept at an initial dose of 1.0 mg/kg subcutaneously every 3 weeks |
Gecacitinib will be administered orally at 100 mg twice daily in the fasting state. Dose adjustments will be based primarily on platelet counts and absolute neutrophil counts. Gecacitinib will be interrupted if the platelet count falls below 50 × 10^9/L and may be resumed when the platelet count recovers to at least 50 × 10^9/L. Luspatercept will be administered by subcutaneous injection at an initial dose of 1.0 mg/kg every 3 weeks. The dose may be adjusted according to blood counts, up to a maximum of 1.75 mg/kg. Treatment may be interrupted if the predose hemoglobin level is at least 120 g/L or if hemoglobin increases rapidly by more than 20 g/L. |
研究衡量的是什么?
主要结果指标
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Percentage of Participants Achieving an Anemia Response
大体时间:24 week
|
Anemia response is defined as conversion from red blood cell transfusion dependence at baseline to transfusion independence, or an increase in hemoglobin of at least 20 g/L in participants who do not require red blood cell transfusions and have a baseline hemoglobin level of 100 g/L or lower. |
24 week
|
次要结果测量
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Percentage of Participants With a Sustained Increase in Mean Hemoglobin of at Least 1.0 g/dL Without Transfusion
大体时间:24 week
|
Percentage of participants achieving an increase in mean hemoglobin of at least 1.0 g/dL from baseline for at least 12 consecutive weeks without red blood cell transfusions. |
24 week
|
|
Time to Anemia Response
大体时间:week 24
|
Time from the first dose of study treatment to the first documented anemia response. |
week 24
|
|
Duration of Anemia Response
大体时间:week 24
|
The longest continuous duration of anemia response among participants who achieve an anemia response. |
week 24
|
|
Change From Baseline in Red Blood Cell Transfusion Amount and Frequency
大体时间:week 24
|
Changes from baseline in the amount and frequency of red blood cell transfusions during study treatment. |
week 24
|
|
Change From Baseline in Hemoglobin
大体时间:weeks 4, 8, 12, 16, 20, and 24
|
Change in hemoglobin concentration, measured in g/L, from baseline at scheduled treatment-period visits. |
weeks 4, 8, 12, 16, 20, and 24
|
|
SVR35
大体时间:week 12 and 24
|
Percentage of participants achieving a reduction in spleen volume of at least 35% from baseline. |
week 12 and 24
|
|
DoMSR
大体时间:week 24
|
Time from the first documented reduction in spleen volume of more than 35% from baseline to the first subsequent assessment showing a reduction of less than 35% from baseline. |
week 24
|
|
MPN-SAF TSS
大体时间:weeks 4, 8, 12, 16, 20, and 24
|
Percentage of participants achieving a reduction of at least 50% from baseline in the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS). |
weeks 4, 8, 12, 16, 20, and 24
|
|
Reduction in Fatigue Score
大体时间:week 24
|
Percentage of participants achieving a reduction of at least 50% from baseline in fatigue symptom score. |
week 24
|
|
Adverse Events
大体时间:From the first dose through 28 days after the last dose.
|
Incidence and severity of adverse events, including events that develop or worsen during treatment and events occurring after treatment that are considered related to the study drugs by the investigator. Serious adverse events and adverse events leading to treatment interruption or discontinuation will also be recorded. |
From the first dose through 28 days after the last dose.
|
|
PFS
大体时间:12 month
|
Time from the first dose of study treatment to disease progression or death from any cause, whichever occurs first. |
12 month
|
|
OS
大体时间:12 month
|
Time from the first dose of study treatment to death from any cause. |
12 month
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (估计的)
学习开始
初级完成 (估计的)
初级完成
研究完成 (估计的)
研究完成
研究注册日期
首次提交
首次提交
首先提交符合 QC 标准的
首先提交符合 QC 标准的
首次发布 (实际的)
首次发布
研究记录更新
最后更新发布 (实际的)
最后更新发布
上次提交的符合 QC 标准的更新
上次提交的符合 QC 标准的更新
最后验证
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.